Synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-15. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
In the early stages of the Syrian civil war, when Assad was reported as "perpetrating massacres of his own people", Galloway said Assad's opponents were "trying to pressure Syria and President Assad because of the good things that he did, such as supporting Palestinian and Lebanese resistance and rejecting to surrender to Israel".
== Pharmacokinetics == Some pharmacokinetic data on hyperforin is available for an extract containing 5% hyperforin. Maximal plasma levels (Cmax) in human volunteers were reached 3–4 hours after administration of an extract containing 14.8 mg hyperforin. Biological half-life (t1/2) and mean residence time were 9 hours and 12 hours, respectively, with an estimated steady state plasma concentration of 100 ng/mL (approx. 180 nM) for 3 doses per day. Linear plasma concentrations were observed within a normal dosage range and no accumulation occurred. In healthy male volunteers, 612 mg dry extract of St. John's wort produced hyperforin pharmacokinetics characterized by a half-life of 19.64 hours.
=== Controversy === The game faced scrutiny in Germany after being linked to the Erfurt school massacre in 2002 after it was found on the computer of the perpetrator, Robert Steinhäuser. Politicians, including Günther Beckstein, and media outlets, particularly Bild, then regularly referred to the game as Killerspiel 'killer game'. Calls for banning violent video games intensified, with politicians like Beckstein advocating for penalties against players. Media outlets like Frontal 21 on ZDF often portrayed players negatively. In 2002, Germany's BPjM considered indexing Counter-Strike but ultimately rejected it, concluding that the game's objectives could be achieved without violence and that its communication aspects were beneficial. Chancellor Gerhard Schröder criticized the decision as irresponsible. A Brazilian federal judge, Carlos Alberto Simões de Tomaz, ordered a ban on the sale of Counter-Strike and EverQuest in October 2007 arguing that the games "bring imminent stimulus to the subversion of the social order, attempting against the democratic state and the law and against public security". The order began to be enforced on January 17, 2008, but regional federal court order lifting the prohibition on the sale of Counter-Strike was published on June 18, 2009.
Sources: en.wikipedia.org
Cells in all organisms regulate gene expression by turnover of gene transcripts (single stranded RNA): The amount of an expressed gene in a cell can be measured by the number of copies of an RNA transcript of that gene present in a sample. In order to robustly detect and quantify gene expression from small amounts of RNA, amplification of the gene transcript is necessary. The polymerase chain reaction (PCR) is a common method for amplifying DNA; for RNA-based PCR the RNA sample is first reverse-transcribed to complementary DNA (cDNA) with reverse transcriptase. In order to amplify small amounts of DNA, the same methodology is used as in conventional PCR using a DNA template, at least one pair of specific primers, deoxyribonucleotide triphosphates, a suitable buffer solution and a thermo-stable DNA polymerase. A substance marked with a fluorophore is added to this mixture in a thermal cycler that contains sensors for measuring the fluorescence of the fluorophore after it has been excited at the required wavelength allowing the generation rate to be measured for one or more specific products. This allows the rate of generation of the amplified product to be measured at each PCR cycle. The data thus generated can be analysed by computer software to calculate relative gene expression (or mRNA copy number) in several samples. Quantitative PCR can also be applied to the detection and quantification of DNA in samples to determine the presence and abundance of a particular DNA sequence in these samples.
==== Member of the Order of the British Empire (MBE) ==== Military Division Royal Navy Chief Petty Officer (Operations) (Radar) Alan James Baker, D077088R. Chief Petty Officer Air Engineering Artificer (L) Stephen Michael Baker, D109087R. Lieutenant Commander Harry Colin Cook. Lieutenant Commander Alan Robert Cronin. Lieutenant Commander Reginald Keith Elsworth. Lieutenant Commander David Michael Foster. Sergeant Steven Paul Goodwin, Royal Marines, P040469W. Lieutenant Commander (SCC) Denise Lilian Gravestock, Royal Navy Reserve. Lieutenant Commander (Acting Commander) Hubert Frederick Hatton. Warrant Officer Peter Robert Jones. Lieutenant Commander Simon John Nicholson Kings. Warrant Officer Michael Stephen Lacey. Warrant Officer Class 1 Peter Lawton, Royal Marines. Lieutenant Commander (now Commander) Christopher Charles Leggett. Lieutenant Commander Anthony Joseph Mawson. Warrant Officer Harold Milne. Lieutenant Commander (now Acting Commander) Geoffrey Charles Pell. Chief Petty Officer (Diver) John Robert Smith, D053657P. Colour Sergeant Alan Keith Turner, Royal Marines, P032549Y. Warrant Officer Nigel Frank Wallace. Lieutenant (now Lieutenant Commander) Geoffrey Ian Woodford. Warrant Officer Simon Yui Kwok Choi. Army The Reverend John Stephen Alker (513792), Chaplain to the Forces (3rd Class), Royal Army Chaplains' Department. Major James Victor Glen Bain (520977), The Argyll and Sutherland Highlanders. 24821742 Corporal Christopher David Ernest Bessey, The Royal Logistic Corps. Lieutenant Russell John Bishop (546098), The Parachute Regiment.
Spironolactone is not generally used in men for the treatment of androgen-dependent dermatological conditions because of its feminizing side effects, but it is effective for such indications in men similarly. As an example, spironolactone has been reported to reduce symptoms of acne in males. An additional example is the usefulness of spironolactone as an antiandrogen in transgender women and nonbinary individuals. Topical spironolactone is effective in the treatment of acne, as well. As a result, topical pharmaceutical formulations containing 2 or 5% spironolactone cream became available in Italy for the treatment of acne and hirsutism in the early 1990s. The products were discontinued in 2006 when the creams were added to the list of doping substances with a decree of the Ministry of Health that year.
=== Wine laws and regulations === In the United States, the Alcohol and Tobacco Tax and Trade Bureau (TTB) limits the use of diammonium phosphate as a nitrogen additive to 968 mg/L (8 lbs/1000 gal) which provides 203 mg N/L of YAN. In the European Union, most countries follow the guidelines of the International Organisation of Vine and Wine (OIV) which dictates a limit of 300 mg/L. In Australia, the limit is based on the level of inorganic phosphate with a maximum limit of 400 mg/L of phosphate permitted.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.